Quick Answer
Kura Oncology, Inc. reported Long Term Debt of $9.71 million for the year ending 2025.
- Kura Oncology, Inc. showed an increase of +40.4% in Long Term Debt from 2024 to 2025.
- This data is from Kura Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $7.29 million | Q3 2016: $7.31 million | Q1 2017: $7.34 million | Q2 2017: $6.86 million | Q3 2017: $6.02 million | Q1 2018: $4.86 million | Q2 2018: $4.15 million | Q3 2018: $3.43 million | Q1 2019: $7.50 million | Q2 2019: $7.50 million | Q3 2019: $7.50 million | Q1 2020: $6.50 million | Q2 2020: $5.75 million | Q3 2020: $5.00 million | Q1 2021: $3.50 million | Q1 2023: $9.20 million | Q2 2023: $9.24 million | Q3 2023: $9.29 million | Q1 2024: $9.38 million | Q2 2024: $8.58 million | Q3 2024: $7.76 million | Q1 2025: $7.65 million | Q2 2025: $6.51 million | Q3 2025: $5.34 million.
- Over the full 9 years of available data (2016 to 2025), Kura Oncology, Inc.'s Long Term Debt has grown by 32.6%.
- Historical annual values: Fiscal year 2025: $9.71 million | Fiscal year 2024: $6.92 million | Fiscal year 2023: $9.33 million | Fiscal year 2022: $9.16 million | Fiscal year 2020: $4.25 million | Fiscal year 2019: $7.25 million | Fiscal year 2018: $7.50 million | Fiscal year 2017: $5.57 million | Fiscal year 2016: $7.32 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: